Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treat...

Full description

Bibliographic Details
Main Authors:	Alina Rosinha, Carlos Rabaça, Fernando Calais, João Moreira Pinto, João Vasco Barreira, Ricardo Fernandes, Rodrigo Ramos, Ana Cristina Fialho, José Palma dos Reis
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Oncology
Subjects:	high-risk identification non-metastatic castration-resistant prostate cancer prostate-specific antigen prostate-specific antigen doubling time standardization
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1266369/full

Similar Items

Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: Sangwon Han, et al.
Published: (2021-04-01)

The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients
by: Tony Wu, et al.
Published: (2016-12-01)

Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
by: Geehyun Song, et al.
Published: (2013-09-01)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
by: Atsushi Mizokami, et al.
Published: (2017-01-01)

Prognostic Outcomes and Predictive Factors in Non-Metastatic Castration-Resistant Prostate Cancer Patients Not Treated with Second-Generation Antiandrogens
by: Yu-Jen Wang, et al.
Published: (2024-10-01)

Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand
by: Bannakij Lojanapiwat, et al.
Published: (2017-03-01)

Prostate-Specific Antigen and Time to PSA Nadir as Prognostic Significance in Castration-Resistant Prostate Cancer
by: Firmantya Hadi Pranata, et al.
Published: (2022-03-01)

Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study
by: Ashley W. Johnston, et al.
Published: (2019-01-01)

Metastatic prostate cancer in the modern era of PSA screening
by: Philip A. Fontenot Jr, et al.

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy
by: Laura Dupuy, et al.
Published: (2013-06-01)

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
by: Arslaan Javaeed, et al.
Published: (2020-05-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
by: Ting Bu, et al.
Published: (2022-03-01)

Prognostic factors for patients treated with abiraterone
by: Cecília M Alvim, et al.
Published: (2020-02-01)

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer
by: Ahmad Anies Shahab, et al.
Published: (2013-03-01)

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
by: Megan Crumbaker, et al.
Published: (2023-11-01)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
by: Aloysius James, et al.
Published: (2018-01-01)

Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer
by: Sinan Avci, et al.
Published: (2020-04-01)

Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy
by: Darren M. C. Poon, et al.
Published: (2025-02-01)

Survival in Patients With Metastatic Prostate Cancer Undergoing Radiotherapy: The Importance of Prostate-Specific Antigen-Based Stratification
by: Zijian Tian, et al.
Published: (2021-06-01)

Research Progress of 161Tb-PSMA Radioligand Therapy for Prostate Cancer
by: Zhengguo CHEN, et al.
Published: (2024-10-01)

Elevated prostate volume index and prostatic chronic inflammation reduce the number of positive cores at first prostate biopsy set: results in 945 consecutive patients
by: Antonio B. Porcaro, et al.

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Moving ahead of prostate-specific antigen
by: Banyameen Mohamad Iqbal, et al.
Published: (2016-01-01)

Body mass index in relation to prostate-specific antigen-related parameters
by: Dandan Lin, et al.
Published: (2021-09-01)

The Efficiency of the Serum Prostate Specific Antigen Levels in Diagnosing Prostatic Enlargements
by: Ingle SP, et al.
Published: (2013-01-01)

The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer
by: Wietske I. Luining, et al.
Published: (2024-01-01)

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia
by: Yasuhide Kitagawa, et al.
Published: (2015-06-01)

DIAGNOSIS OF PROSTATIC NEOPLASM LATER TO ANTIBIOTIC TREATMENT IN PATIENTS WITH PROSTATE-SPECIFIC ANTIGEN BETWEEN 4 AND 10 ng/ml (IN SPANISH)
by: Infantes-Burgos Ronald Javier, et al.
Published: (2014-01-01)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
by: Panagiotis J. Vlachostergios, et al.
Published: (2021-02-01)

Toward Maximizing Immunotherapy in Metastatic Castration Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
by: Susan F Slovin
Published: (2012-05-01)

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
by: Kai-Jie Wu, et al.
Published: (2018-01-01)

Prostate Specific Antigen (PSA): The Historical Perspective
by: T. Ming Chu
Published: (2020-12-01)

Epidemiological Study of Patients with Prostate Cancer in South of Iraq
by: Manal Badi Salih Al-Tmemi
Published: (2019-07-01)

CUT-OFF VALUES OF PROSTATE SPECIFIC ANTIGEN DENSITY– AN EFFECTIVE SCREENING MARKER BEFORE PROSTATE BIOPSY
by: Zujaja Hina Haroon, et al.
Published: (2022-03-01)

Effect of Temperature and Humidity on Serum Prostate Specific Antigen Levels in Asymptomatic Male Population
by: Murat Tuğrul Eren, et al.
Published: (2016-12-01)

Review of Clinical Manifestations of Biochemically-advanced Prostate Cancer Cases
by: Edmund Chiong, et al.
Published: (2005-07-01)

Possible association between periodontitis and prostatitis: A pilot study
by: Stefanovska Emilija S., et al.
Published: (2021-01-01)

Association of prostate volume with incidence and aggressiveness of prostate cancer
by: Al-Khalil S, et al.
Published: (2016-10-01)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
by: Michael Tzeng, et al.
Published: (2021-08-01)